Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released its annual Companies to Watch report. This year’s report identifies seven innovators trying to change the drug discovery and development paradigm by utilizing innovative artificial intelligence (AI) and machine learning (ML) technologies. Drawing on data and analytics from BioWorld, published by Clarivate, paired with analysis of drug benefits, financing, R&D activity and more, this report explores why Clarivate believes these innovators stand out and what makes them companies to watch. Continue reading
Novartis UK is pleased to announce the launch of the immersive MPN 10 exhibition at Westfield London (White City) which shines a light on the symptoms of a group of rare blood cancers called myeloproliferative neoplasms (MPNs). The 10 bespoke sculptures have been exclusively designed by five mural artists from around the UK, with London Artist, Frankie Strand, designing numbers 7 and 9. Continue reading
Today Economist Impact, an arm of The Economist Group that works with organisations globally to further their missions, released research supported by Chiesi Group, a pharmaceutical company, exploring the links between air quality, health inequalities and lung health. A survey of 500 people found that, despite reductions in the concentration of key air pollutants, poor air quality negatively affects symptoms, overall health and quality of life for people living with lung conditions. Continue reading
Today, Acorai, a start-up medical device manufacturer from Sweden, has announced the initiation of a global clinical trial with the enrollment of its first patient in London, UK. Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024. Continue reading
An Icahn School of Medicine at Mount Sinai study sheds light on the intricate interplay between mammary adipose (fat) tissue and breast health, and offers exciting possibilities for understanding breast development, lactation, cancer, and obesity and related metabolic disorders. Continue reading
During the Women’s FIFA World Cup, it has been wonderful to see the spotlight turn to female athletes.
There’s always been more research on male athletes compared to female athletes, but the gap is narrowing.
One thing we still don’t know enough about is the effect of the menstrual cycle on athletic performance.
The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancement in Alzheimer’s research and treatment. The full Phase 3 data was reported at the Alzheimer’s Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online. The data were simultaneously published in the Journal of the American Medical Association. Continue reading
Roche (SIX: RO, ROG; OTCQX: RHHBY) introduces its navify® Algorithm Suite, a single platform hosting a library of digital medical algorithms that generate patient-centric insights and can aid earlier diagnosis of cancer and other conditions per intended use, at the HIMSS Global Conference in Chicago, USA, from April 17- 21, 2023. Continue reading
QC Ware, a leading quantum software and services company, announced today that a joint research project with one of the world’s leading biotechnology companies uncovered new discoveries in medical imaging analysis and diagnostics, leveraging quantum computing to better detect the presence and type of diabetic retinopathy. Continue reading
Proposed combination enhances Pfizer’s position as a leading company in Oncology
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio
Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030
Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today
NEW YORK & BOTHELL, Wash.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction. Continue reading